Despite consistent reductions in the severity of hepatic steatosis following PLIN2 ablation, the influence of hepatic PLIN2 loss on the development NAFLD comorbidities such as obesity and insulin resistance during disease progression remains unresolved. This evidence concerns the gene PLIN2 and metabolic dysfunction-associated steatotic liver disease.